试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-07
Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19
编号:NCT04474483登记状态:提前终止企业 / 申办者:State University of New York at Buffalo
药物 / 成分:Melatonin、Placebo (Methylcellulose) capsule
登记的停止原因(原文):difficult recruitment and complete first visit in person during thne hight of tne pandemic and later not enough subjects
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-07
A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors
编号:NCT05430555登记状态:提前终止企业 / 申办者:T-knife GmbH
药物 / 成分:Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR
登记的停止原因(原文):Sponsor decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-06
Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism
编号:NCT00467987登记状态:提前终止企业 / 申办者:University at Buffalo
药物 / 成分:androgel、placebo
登记的停止原因(原文):Company no longer making same drug doses.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-06
Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)
编号:NCT00550862登记状态:提前终止企业 / 申办者:Intercept Pharmaceuticals
药物 / 成分:INT-747、Ursodeoxycholic Acid (URSO)、Placebo
登记的停止原因(原文):Study stopped by sponsor due to administrative reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-06
Diabetes Prevention With Lifestyle Intervention and Metformin Escalation
编号:NCT03258723登记状态:提前终止企业 / 申办者:Yale University
药物 / 成分:Lifestyle Intervention、Metformin
登记的停止原因(原文):COVID-19 led to changes in study design and an early end to data collection.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-06
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
编号:NCT03684694登记状态:提前终止企业 / 申办者:ADC Therapeutics S.A.
药物 / 成分:Loncastuximab Tesirine、Ibrutinib
登记的停止原因(原文):Administrative decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-06
Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)
编号:NCT03722966登记状态:提前终止企业 / 申办者:University of Oklahoma
药物 / 成分:Varenicline、Oral Nicotine Replacement Therapy (NRT)、Medication Reminders、Tobacco Cessation Counseling
登记的停止原因(原文):Following the Chantix recall, Pfizer stopped providing medication for the study and and new study enrollments were discontinued.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-06
Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia
编号:NCT04403763登记状态:提前终止企业 / 申办者:AbbVie
药物 / 成分:AGN-241622、Vehicle
登记的停止原因(原文):Strategic considerations
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-06
Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19
编号:NCT04805671登记状态:提前终止企业 / 申办者:Invivyd, Inc.
药物 / 成分:ADG20、Normal saline
登记的停止原因(原文):All primary efficacy data has been collected and analyzed. Based on the safety data gathered to date, it has been determined that continued participation by study subjects would not yield any additional beneficial safety information.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-05
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
编号:NCT03209401登记状态:提前终止企业 / 申办者:Georgetown University
药物 / 成分:Niraparib、Carboplatin
登记的停止原因(原文):Lack of accrual
查看官方原始记录 ↗